Back to Search Start Over

Harnessing Redox Polymer Dynamics for Enhanced Glucose-Oxygen Coupling in Dual Biosensing and Therapeutic Applications.

Authors :
El Housseini W
Baiarashov E
Gerulskis R
Milam A
Minteer SD
Source :
ACS sensors [ACS Sens] 2024 Jun 28; Vol. 9 (6), pp. 3357-3366. Date of Electronic Publication: 2024 Jun 06.
Publication Year :
2024

Abstract

The burgeoning field of continuous glucose monitoring (CGM) for diabetes management faces significant challenges, particularly in achieving precise and stable biosensor performance under changing environmental conditions such as varying glucose concentrations and O <subscript>2</subscript> levels. To address this, we present a novel biosensor based on the electroless coupling of glucose oxidation catalyzed by flavin-dependent glucose dehydrogenase (FAD-GDH) and O <subscript>2</subscript> reduction catalyzed by bilirubin oxidase (BOD) via a redox polymer, dimethylferrocene-modified linear poly(ethylenimine), FcMe <subscript>2</subscript> -LPEI. Initial cyclic voltammetry tests confirm the colocalization of both enzymatic reactions within the potential range of the polymer, indicating an effective electron shuttle mechanism. As a result, we created a hybrid biosensor that operates at open-circuit potential (OCP). It can detect glucose concentrations of up to 100 mM under various O <subscript>2</subscript> conditions, including ambient air. This resulted from optimizing the enzyme ratio to 120 ± 10 mU <subscript>BOD</subscript> ·U <subscript>FAD-GDH</subscript> <superscript>-1</superscript> ·atm <subscript>O <subscript>2</subscript> </subscript> <superscript>-1</superscript> . This biosensor is highly sensitive, a crucial feature for CGM applications. This distinguishes it from FAD-GDH traditional biosensors, which require a potential to be applied to measure glucose concentrations up to 30 mM. In addition, this biosensor demonstrates the ability to function as a noninvasive, external device that can adapt to changing glucose levels, paving the way for its use in diabetes care and, potentially, personalized healthcare devices. Furthermore, by leveraging the altered metabolic pathways in tumor cells, this system architecture opened up new avenues for targeted glucose scavenging and O <subscript>2</subscript> reduction in cancer therapy.

Details

Language :
English
ISSN :
2379-3694
Volume :
9
Issue :
6
Database :
MEDLINE
Journal :
ACS sensors
Publication Type :
Academic Journal
Accession number :
38842796
Full Text :
https://doi.org/10.1021/acssensors.4c00685